Expert Perspectives in HF Lesson 5: Integrating Ivabradine

PROGRAM DESCRIPTION In 2015, the US Food and Drug Administration (FDA) approved ivabradine, making it one of the first pharmacologic therapies to emerge for chronic heart failure (HF) management in ...

PROGRAM DESCRIPTION
In 2015, the US Food and Drug Administration (FDA) approved ivabradine, making it one of the first pharmacologic therapies to emerge for chronic heart failure (HF) management in more than a decade. Approval was based on the results of the SHIFT trial, which enrolled 6558 patients with symptomatic chronic HF, an ejection fraction (EF) of ≤35%, and a heart rate (HR) of ≥70 beats per minute (bpm) and randomized them to either ivabradine or placebo. The majority of patients were on stable therapy with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) and beta-blockers, and many were on a mineralocorticoid receptor antagonist (MRA) as well. The study found an 18% relative risk reduction for the primary outcome of cardiovascular death or hospital admission for worsening HF. Additional analyses found a reduced risk of hospitalization, reverse remodeling, and improved quality of life with ivabradine compared with placebo.

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be better able to:Evaluate the safety, efficacy, and mechanism of action of ivabradineUtilize ivabradine in patients as appropriate

---

Write the first review

Resource tags